Zobrazeno 1 - 10
of 15
pro vyhledávání: '"L Lombera"'
Autor:
A. Etxeberria, J. Iribar, K. Vrotsou, R. Rotaeche, I. Barral, J. Belzunegui, A. Bustinduy, J. Caso, C. Del Bosque, O. Frias, A. Lekuona, L. Lombera, B. López, J. Núñez, B. Olasagasti, I. Royo, E. Zapata, X. Zubeldia
Publikováno v:
Journal of Healthcare Quality Research. 36:91-97
Resumen Introduccion y objetivos Evaluar la implementacion de una experiencia colaborativa entre atencion primaria (AP) y hospitalaria (AH) dirigida a disminuir la prescripcion potencialmente inapropiada (PPI) en pacientes polimedicados. Materiales y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1af3a394753ba7d08cb3526acb16c685
https://doi.org/10.1016/j.jhqr.2020.09.005
https://doi.org/10.1016/j.jhqr.2020.09.005
Autor:
A, Etxeberria, J, Iribar, K, Vrotsou, R, Rotaeche, I, Barral, J, Belzunegui, A, Bustinduy, J, Caso, C, Del Bosque, O, Frias, A, Lekuona, L, Lombera, B, López, J, Núñez, B, Olasagasti, I, Royo, E, Zapata, X, Zubeldia
Publikováno v:
Journal of healthcare quality research. 36(2)
To evaluate the implementation of a collaborative experience between Primary (PC) and Hospital Care (HC) aimed at reducing potentially inappropriate prescribing (PIP) in patients with polypharmacy.Collaborative experience including a controlled befor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89a4e96862c4ef7e4ffb3d005de6593d
https://pubmed.ncbi.nlm.nih.gov/33495114
https://pubmed.ncbi.nlm.nih.gov/33495114
Autor:
P Pascual Gonzalez, MJ Gayan Lera, L Lombera Saez, D García Echeverría, J Landa Alberdi, MP Carmona Oyaga, T Gonzalez Fernandez, I Aldalur Uranga, A Zurutuza Lopez, MP Bachiller Cacho
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Vancomycin is a glucopeptide antibiotic widely used to treat Gram positive related infections. It is well known for its nefrotoxic and ototoxic profile, but neutropaenia and thrombocytopaenia are not so well described. Purpose The aim of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d0d1da0d5820be91cd522cdf5c00c47
https://doi.org/10.1136/ejhpharm-2019-eahpconf.209
https://doi.org/10.1136/ejhpharm-2019-eahpconf.209
Autor:
D García, MP Bachiller, A Zurutuza, MP Carmona, MJ Gayán, L Lombera, G Lopez, C Ripa, T Gonzalez, P. Pascual, J Landa
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background The therapeutic strategy for chronic hepatitis C (CHC) in our health system established that in mono- or co-infected HCV/HIV patients in whom prioritised therapy with glecaprevir/pibrentasvir is contraindicated, their chronic medication (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d72968bb80dffc2e8c430ca76a2533a4
https://doi.org/10.1136/ejhpharm-2019-eahpconf.247
https://doi.org/10.1136/ejhpharm-2019-eahpconf.247
Autor:
J Landa Alberdi, L Lombera Saez, MP Carmona Oyaga, LM Mendarte Barrenechea, MJ Gayan Lera, G Lopez Arzoz, Mauelon Echeverria, A Zurutuza Lopez, MP Bachiller Cacho, JA Iribarren Loyarte
Publikováno v:
Section 1: Introductory Statements and Governance.
Background Following a request by the Central Management Organisation of our Health System (HS), a decision was made to change from a patented drug of three active principals, emtricitabine/tenofovir-disopropilo/rilpivirine (FTC/TDF/RPV) to two drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84b0c6339a4d52742b097d5a02441d52
https://doi.org/10.1136/ejhpharm-2019-eahpconf.5
https://doi.org/10.1136/ejhpharm-2019-eahpconf.5
Autor:
A Lizardi, J. Barral, Paula Carmona, MP Bachiller, M. Ariztia, B. Odriozola, P. Pascual, L Leunda, M Ercilla, C Ripa, I. Urreta, MJ Gayán, L Lombera
Publikováno v:
Clinical Nutrition. 37:S157-S158
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da2fe0fce0d9a313a0dd11b28ccb620b
https://doi.org/10.1016/j.clnu.2018.06.1578
https://doi.org/10.1016/j.clnu.2018.06.1578
Autor:
M. Ercilla, C. Ripa, M. Ariztia, I. Urreta, M.J. Gayán, M.P. Carmona, P. Pascual, L. Leunda, A. Lizardi, J. Barral, B. Odriozola, L. Lombera
Publikováno v:
Clinical Nutrition. 37:S280
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25851d8a05174ceaabc6c90830beafcc
https://doi.org/10.1016/j.clnu.2018.06.1981
https://doi.org/10.1016/j.clnu.2018.06.1981
Autor:
M Ercilla, C Ripa, J. Barral, M. Ariztia, L Leunda, L Lombera, I. Urreta, A Lizardi, P. Pascual, MJ Gayán, B. Odriozola, Paula Carmona
Publikováno v:
Clinical Nutrition. 37:S158
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36b19bf089381ba856f7604792fc269c
https://doi.org/10.1016/j.clnu.2018.06.1579
https://doi.org/10.1016/j.clnu.2018.06.1579
Autor:
B. Irastorza, L Lombera, M Urretavizcaya, P Bachiller, M Ercilla, M Umerez, A Lizardi, A Zurutuza, L Leunda, G Lizeaga
Publikováno v:
European Journal of Hospital Pharmacy. 23:A214.2-A214
Background Calcinosis cutis is caused by accumulation of calcium salts in the tissues, with subcutaneous nodules, atrophy and ulceration over the affected area. The therapeutic approach is not clearly established, particularly in neonates. Purpose To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::545d959255b6c01c4a8066f2e1cb182f
https://doi.org/10.1136/ejhpharm-2016-000875.485
https://doi.org/10.1136/ejhpharm-2016-000875.485
Autor:
MP Bachiller, M Ercilla, MJ Gayán, L Lombera, G Lopez, A Lizardi, José Antonio Iribarren, Paula Carmona, C Ripa, M Von Wichmann
Publikováno v:
European Journal of Hospital Pharmacy. 22:A33.1-A33
Background Triple therapy-based treatment with protease inhibitors in infected genotype 1 hepatitis C (HCV) patients improves efficacy measured as sustained virological response (SVR). Purpose To compare the effectiveness and safety of triple therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12fd7777ad05c08e6d796c568384210c
https://doi.org/10.1136/ejhpharm-2015-000639.78
https://doi.org/10.1136/ejhpharm-2015-000639.78